<SEC-DOCUMENT>0001193125-18-072339.txt : 20180307
<SEC-HEADER>0001193125-18-072339.hdr.sgml : 20180307
<ACCEPTANCE-DATETIME>20180306183208
ACCESSION NUMBER:		0001193125-18-072339
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20180306
FILED AS OF DATE:		20180307
DATE AS OF CHANGE:		20180306

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		18671328

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		612 9276 1224

	MAIL ADDRESS:	
		STREET 1:		LEVEL 12, 95 PITT STREET
		CITY:			SYDNEY, NEW SOUTH WALES
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d547468d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>FORM 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 6-K
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Dated March&nbsp;6, 2018 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number 001-35428 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP
LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level 12, 95 Pitt Street </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Sydney, 2000 New South Wales, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&nbsp;&nbsp;&#9746; Form
40-F&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)
(1):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)
(7):&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing
the information to the Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&nbsp;&nbsp;&#9744;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;&#9746;
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule 12g3-2(b): Not applicable. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="font-size:6pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:25.30pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:75.45pt; display:inline; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">IMMUTEP ANNOUNCES UNITED STATES PATENT GRANT FOR IMP701 ANTIBODY</P></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: March&nbsp;6, 2018 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="6%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name: Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U></U>Title:&nbsp;&nbsp;&nbsp;Chief Executive Officer</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d547468dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit&nbsp;99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g547468g04f73.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>ASX/Media Release (Code: ASX: IMM; NASDAQ: IMMP) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6&nbsp;March 2018 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP ANNOUNCES UNITED
STATES PATENT GRANT FOR IMP701 ANTIBODY </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SYDNEY, AUSTRALIA &#150; Immutep Limited (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148;, the
&#147;Company&#148;) announces the grant of patent no.&nbsp;9,908,936 entitled &#147;Antibody molecules to LAG-3 and uses thereof&#148; by the United States Patent and Trade Mark Office. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patent was filed as a divisional application and is directed to LAG525, a humanised form of Immutep&#146;s IMP701 antibody that was originally developed
by Immutep S.A.S., now a wholly owned subsidiary of the Company. The patent is co-owned by Novartis AG and Immutep S.A.S. and will expire on 13&nbsp;March 2035. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About IMP701 and LAG525 </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IMP701 is a therapeutic antibody
originally developed by Immutep S.A.S. to target LAG-3. This antagonist antibody plays a role in controlling the signalling pathways in both effector T cells and regulatory T cells (Treg). The antibody works to both activate effector T cells (by
blocking inhibitory signals that would otherwise switch them off) and at the same time inhibit Treg function that normally prevent T cells from responding to antigen stimulation. The antibody therefore removes two brakes that prevent the immune
system from responding to and killing cancer cells. In contrast, some other checkpoint antibodies in development target only the effector T&nbsp;cell pathway and don&#146;t address the Treg pathway. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Rights to the development and commercialisation of IMP701 were licensed to CoStim Pharmaceuticals in 2012, which was subsequently acquired by Novartis in
2014. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">LAG525, a humanised form of IMP701 is currently being evaluated in a Phase I/II clinical trial and a Phase II clinical trial, in combination with
Novartis&#146; PD1 inhibitor PDR001 for the treatment of cancer. Novartis has full responsibility for the continued development of the antibody program and Immutep is eligible to receive development-based milestone payments and royalties on sales
following commercialisation of the antibody. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Further information on the clinical studies may be obtained at: </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">https://clinicaltrials.gov/ct2/show/NCT02460224 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">https://clinicaltrials.gov/ct2/show/NCT03365791 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About
Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a globally active biotechnology company that is a leader in the development of immunotherapeutic products for the treatment of
cancer and autoimmune disease. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximise value to shareholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g547468g04f73.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep&#146;s current lead product is eftilagimod alpha (&#147;efti&#148; or &#147;IMP321&#148;), a soluble LAG-3Ig fusion
protein based on the <FONT STYLE="white-space:nowrap">LAG-3</FONT> immune control mechanism. This mechanism plays a vital role in the regulation of the T cell immune response. Eftilagimod alpha alone, or in other drug combinations, has completed
early Phase II trials as an APC activator boosting T cell responses for cancer chemo-immunotherapy. A number of additional LAG-3 products, including antibodies for immune response modulation in autoimmunity and cancer are being developed by
Immutep&#146;s large pharmaceutical partners. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is listed on the Australian Stock Exchange (IMM), and on the NASDAQ (IMMP) in the U.S. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For further information please contact: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S.
Investors: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jay Campbell, Vice President of Business Development and Investor Relations, Immutep Limited </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (917)&nbsp;860-9404; <U>jay.campbell@immutep.com</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthew
Beck, The Trout Group LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (646)&nbsp;378-2933; <U>mbeck@troutgroup.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Matthew Gregorowski,
Citadel-MAGNUS </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 2 8234 0105; <U>mgregorowski@citadelmagnus.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please also refer to Immutep&#146;s new website for further information: <U>www.immutep.com</U> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2 </P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g547468g04f73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g547468g04f73.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X1#N17AI9@  34T *@    @ ! $[  (
M   ,   (2H=I  0    !   (5IR=  $    8   0SNH<  <   @,    /@
M   <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 $1A;6EO;B!"
M=6YZ   %D ,  @   !0  !"DD 0  @   !0  !"XDI$  @    ,X-   DI(
M @    ,X-   ZAP !P  " P   B8     !SJ    "
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M*BHJ*BHJ*O_  !$( ' "S ,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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M>>-KF7MJ?+SWT.BHKA%^).9.=-&WVGY_E5^X^(6FQVJ/!!-+*PYC("[/J?\
M#-3[2'<A8FD^IUE%<1;?$>)Y0+JP9(R>6CDW$?A@5V=O<17=M'/;N)(I%#*P
M[@U49*6QI"K"I\+)**XRZ^(MO%(Z0:?*^UBNYY O3\Z9:_$>%Y@MW8-'&3@O
M')NV_A@5/M(=S/ZS2O:YVU%<=??$2SAD*6-J]P!_RT=M@/T[U8T?QU::C=I;
M74#6LDAVHQ;<I/IGM3]I&]KC6(I-\MSJ:*S?$&L+H.ASZE)"TZP[<QJV"<L!
MU_&J7A/Q5'XJM;B>*U>V$$@0AW#9R,YXJS<WZCN;B*TM9;FX;9%"A=VQG"@9
M)K!\6>+HO"B6K2V<ES]I+ ;'"[=N/7ZTMSJBZU\.[O44B:%;BQE<(QR5^4]Z
M )M$\6Z5XANYK?2Y))6A0.S-&5&"<<9K;KPKP9XJB\*W=S/-:O<B>-4 1PN,
M'/>O2O"OCN#Q3J,UI#8R6YBB\TL\@;/(&./K0!U=%9'B'Q-I_AJS6;4')=\B
M*&,9>0^P]/>N(/QA_P!(P-''EYZ?:?F_]!Q0!Z=16/X=\3V'B:S::P9E>,@2
MPR<-&?ZCWK&\2_$2U\/:I)IYL)KB>-59B&"KR,CGD_I0!V-<QXZTJ74-'2XM
MU+R6K%RH')4CG'Z&N9C^,(,GSZ/\G^S<\_\ H-=IX=\4Z;XFMV>P=EECQYD$
M@PZ>_N/<4I+F5B)P4XN+.,T?7;GPWHJ/&8+I+MRR0[^8L<$G'KQ^59E]J4^O
M73&:U62^F=5B:+(PO]S'?KUKT.^\'Z-?SF:2V\J1CEC"Q3=^'2K6F>'M-TAM
MUE;!9",&1B6;\STK#V<GI?0XOJ]5VBW[I)HM@=+T6ULV.6B3#$?WCR?U-7J*
M*W6BL=Z22L@HHHIC"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "HKG
M_CTE_P!QOY5+45S_ ,>DO^XW\J!/8\Y^'W_(Q-_U[-_-:9X[_P"1J/\ UQC_
M *T_X??\C$W_ %[-_-:9X[_Y&L_]<H_ZUR?\NSR?^8;YG=W>BZ?=Z9) UG H
M:,X*Q@%3C@@BN!\$007'B(17<$<X\EB!(N0"".<5Z=_RP_X#_2O-/ O_ "-:
M_P#7*3^E:S2YHG37BE5@;?CW2K2/2(KR"".*5)0A**%W*<]<>^*N^ 96D\,A
M6.?+F=1[#@_UH\??\BP?^NZ4SX>_\BY)_P!?+?R6C:H-)+$Z=CEO"D,<_C)8
MYXUD0F4E74$=^QKH_'6E6BZ&+N&WCBEBD4;D4#*DXP<?A7/^#_\ D=D^LO\
M(UUOCK_D5)_^ND?_ *$*B*7LV8THIX>5_,SO -I:7&CS236L,DJSE2[H"2,
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M5\3DFM58Q3WBNO'(C3')_!?UH ]PHHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M >>?\+%U#_GQMO\ OIJ/^%BZA_SXVW_?35U7_"):%_T#HOS;_&C_ (1+0O\
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MC_A$M"_Z!T7YM_C1RU.X>RQ/\W]?<<K_ ,+%U#_GQMO^^FH_X6+J'_/C;?\
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;_P :/^$2T+_H'1?FW^-'+4[A[+$_S?U]Q__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
